doi: 10.1038/nrm3412 133 RosenblatJ
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial PMID: 37385280 Lancet
Symptoms that are particularly concerning include ongoing vomiting, severe diarrhea, or intense abdominal pain
If so, what steps are required
Due to the popularity of Semaglutide and Tirzepatide, many pharmacies have compounded these products to help alleviate the drug shortage crisis
Kirtleys story is one many South Floridians are telling in exam rooms and waiting areas as prescriptions for GLP1 drugs climb and clinicians and researchers tally both the eyecatching benefits and a new wave of safety questions